The Caspase 1 pipeline drugs market research report outlays comprehensive information on the Caspase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Caspase 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Dermatology, Immunology, Metabolic Disorders, and Central Nervous System which include the indications Epidermolysis Bullosa, Atopic Dermatitis (Atopic Eczema), Inflammation, Autoimmune Disorders, Familial Mediterranean Fever, and Neuroinflammation. It also reviews key players involved in Caspase 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Caspase 1 pipeline targets constitutes close to eight molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 2, 4, and 2 respectively.
Caspase 1 overview
Caspase 1 (CASP1) is a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a important role in the execution-phase of cell apoptosis. It also plays a important role in cell immunity as an inflammatory response initiator: once activated through formation of an inflammasome complex, it initiates a pro-inflammatory response through the cleavage of the two inflammatory cytokines IL1B and IL18, releasing the mature cytokines which are involved in a variety of inflammatory processes. CASP1 cleaves and activates CASP7 in response to bacterial infection and promotes plasma membrane repair.
For a complete picture of Caspase 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
